NCT05739630 is a Phase 2, PHASE3 clinical trial of mitoxantrone liposome in Acute Leukemia, sponsored by The First Affiliated Hospital of Soochow University.

Who is sponsoring NCT05739630?

NCT05739630 is sponsored by The First Affiliated Hospital of Soochow University.

What drugs are being tested in NCT05739630?

Interventions in NCT05739630: mitoxantrone liposome, ATG.

What condition does NCT05739630 study?

NCT05739630 studies Acute Leukemia.

Is NCT05739630 still recruiting?

NCT05739630 is currently status unknown. Last updated 22 February 2023.

Last reviewed 2023-02-22 · How we verify

NCT05739630

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia

Status unknown Phase 2, PHASE3 Last updated 22 February 2023

What this trial tests

Phase 2, PHASE3 trial testing mitoxantrone liposome in Acute Leukemia in 60 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
31 January 2024

31 January 2025

Quick facts

Lead sponsor	The First Affiliated Hospital of Soochow University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 January 2023
Primary completion	31 January 2024
Estimated completion	31 January 2025
Sites	1 location across China

Drugs / interventions tested

mitoxantrone liposome
ATG — full drug profile →

Conditions studied

Acute Leukemia — all drugs for Acute Leukemia →

Sponsor

The First Affiliated Hospital of Soochow University

Who can join

Adults 14 to 60, any sex, with Acute Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study intends to evaluate the efficiency and safety of M-PTCy as conditioning regimen in Haploidentical HSCT for Acute Leukemia, so as to provide a new conditioning regimen for allogeneic hematopoietic cell transplantation.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.
Domingues C, Jarak I, Veiga F, Dourado M, et al · · 2023 · cited 33× · PMID 37896191 · DOI 10.3390/pharmaceutics15102431
Tuning mechanical softness as a design principle in drug delivery: A biomechanical perspective.
Qi K, Zhang S, Bi X, Zhang Z, et al · · 2026 · cited 1× · PMID 41909730 · DOI 10.1016/j.apsb.2025.11.037
EHA2024 Hybrid Congress
· 2024

Verify or expand the search:

Other recruiting trials for Acute Leukemia

Currently open trials in the same condition.

NCT07270770 — BY002 IIT Study in R/R Acute Leukemia · Phase 1 · recruiting
NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
NCT07362095 — Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) · Phase 1, PHASE2 · recruiting
NCT07101497 — Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia · Phase 2 · recruiting
NCT06984536 — Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT · Phase 2 · recruiting

Other The First Affiliated Hospital of Soochow University trials

Trials by the same sponsor.

NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05739630 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
Last refreshed: 22 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05739630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing